Graduate education
University of Kentucky (Master of Health Administration Health Administration)[1]
Through 2011
Amit Arbune
Assistant Professor
UT Southwestern Medical Center · Date not established · Last known relationship
Assistant Professor
UT Southwestern Medical Center · Date not established · Last known relationship
Conflicting evidence. The faculty card lists M.D.; the academic profile additionally lists M.H.A.
A cardio-oncologist and advanced cardiac imaging specialist whose work addresses cancer therapy-related cardiotoxicity and the implementation of cardio-oncology services. He serves as Medical Director of the Cardio-Oncology Clinic at Parkland Health.
Amit Arbune is an Assistant Professor in Internal Medicine and a member of the Division of Cardiology. He directs Parkland Health's Cardio-Oncology Clinic and helps lead cardio-oncology education for the Global Cancer Consortium.
His research uses cardiac MRI, CT, PET, strain analysis, and other imaging methods to detect and characterize cardiotoxicity. It also covers immune checkpoint inhibitor myocarditis, chemotherapy-associated injury, complex cardio-oncology cases, and implementation frameworks for building clinical services.
advanced cardiac imaging · cancer therapy-related cardiotoxicity · cardiac CT · cardiac MRI · cardio-oncology · immune checkpoint inhibitor myocarditis · implementation science · PET imaging
Reviewed sources document Graduate education: University of Kentucky (Master of Health Administration Health Administration), Medical school: Mahatma Gandhi Mission's Medical College, India (MD), Residency: St. Elizabeth Youngstown Hospital (Internal Medicine), and Fellowship: MetroHealth Medical Center, plus 2 more training records.
Explore education and trainingReviewed sources document advanced cardiac imaging, cancer therapy-related cardiotoxicity, cardiac CT, and cardiac MRI, plus 4 more research items. Explore attributed publications and research affiliations.
Explore researchDated relationships supported by published source records. Inferred dates are labeled.
Date not established
UT Southwestern Medical Center
UT Southwestern Division of Cardiology faculty directoryUniversity of Kentucky (Master of Health Administration Health Administration)[1]
Through 2011
Mahatma Gandhi Mission's Medical College, India (MD)[1]
Through 2007
St. Elizabeth Youngstown Hospital (Internal Medicine)[1]
Through 2015
MetroHealth Medical Center[1]
Through 2018
Yale New Haven Medical Center (Cardiac Imaging)[1]
Through 2019
Assistant Professor[2]
ECFMG[1]
Through 2011
advanced cardiac imaging[1]
cancer therapy-related cardiotoxicity[1]
cardiac CT[1]
cardiac MRI[1]
cardio-oncology[1]
immune checkpoint inhibitor myocarditis[1]
implementation science[1]
PET imaging[1]
Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.
19 source claims · Reviewed Sep 7, 2026
Biographical context: A cardio-oncologist and advanced cardiac imaging specialist whose work addresses cancer therapy-related cardiotoxicity and the implementation of cardio-oncology services. He serves as Medical Director of the Cardio-Oncology Clinic at Parkland Health.
Biography Amit Arbune, M.D., M.H.A., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Cardiology. He serves as Medical Director for the Cardio-Oncology Clinic at Parkland Health. He also leads the cardio-oncology section for the Global Cancer Consortium and co-directs its certification training, which aims to train cardiologists, hematologists and oncologists, internists, advanced practice providers, and clinical pharmacists in the field of cardio-oncology. Dr. Arbune received his medical education at Mahatma Gandhi Mission's Medical College in India. He completed internal medicine residency training at North East Ohio Medical University in Youngstown, Ohio, followed by fellowship training in cardiovascular disease at Case Western Reserve University in Cleveland, Ohio, and in advanced cardiovascular imaging at Yale University in New Haven, Connecticut. He also holds a master's degree in healthcare administration from the University of Kentucky in Lexington. Prior to joining the UT Southwestern faculty in 2025, he was on the faculty at the University of Kentucky, where he served as the Department of Medicine's Quality and Patient Safety Officer and Founding Director of its Cardio-Oncology program, the only program in the state to be recognized by the International Cardio-Oncology Society's as a Gold Level Center of Excellence. Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Biographical context: Amit Arbune is an Assistant Professor in Internal Medicine and a member of the Division of Cardiology. He directs Parkland Health's Cardio-Oncology Clinic and helps lead cardio-oncology education for the Global Cancer Consortium.
Biography Amit Arbune, M.D., M.H.A., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Cardiology. He serves as Medical Director for the Cardio-Oncology Clinic at Parkland Health. He also leads the cardio-oncology section for the Global Cancer Consortium and co-directs its certification training, which aims to train cardiologists, hematologists and oncologists, internists, advanced practice providers, and clinical pharmacists in the field of cardio-oncology. Dr. Arbune received his medical education at Mahatma Gandhi Mission's Medical College in India. He completed internal medicine residency training at North East Ohio Medical University in Youngstown, Ohio, followed by fellowship training in cardiovascular disease at Case Western Reserve University in Cleveland, Ohio, and in advanced cardiovascular imaging at Yale University in New Haven, Connecticut. He also holds a master's degree in healthcare administration from the University of Kentucky in Lexington. Prior to joining the UT Southwestern faculty in 2025, he was on the faculty at the University of Kentucky, where he served as the Department of Medicine's Quality and Patient Safety Officer and Founding Director of its Cardio-Oncology program, the only program in the state to be recognized by the International Cardio-Oncology Society's as a Gold Level Center of Excellence. Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Biographical context: His research uses cardiac MRI, CT, PET, strain analysis, and other imaging methods to detect and characterize cardiotoxicity. It also covers immune checkpoint inhibitor myocarditis, chemotherapy-associated injury, complex cardio-oncology cases, and implementation frameworks for building clinical services.
Biography Amit Arbune, M.D., M.H.A., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Cardiology. He serves as Medical Director for the Cardio-Oncology Clinic at Parkland Health. He also leads the cardio-oncology section for the Global Cancer Consortium and co-directs its certification training, which aims to train cardiologists, hematologists and oncologists, internists, advanced practice providers, and clinical pharmacists in the field of cardio-oncology. Dr. Arbune received his medical education at Mahatma Gandhi Mission's Medical College in India. He completed internal medicine residency training at North East Ohio Medical University in Youngstown, Ohio, followed by fellowship training in cardiovascular disease at Case Western Reserve University in Cleveland, Ohio, and in advanced cardiovascular imaging at Yale University in New Haven, Connecticut. He also holds a master's degree in healthcare administration from the University of Kentucky in Lexington. Prior to joining the UT Southwestern faculty in 2025, he was on the faculty at the University of Kentucky, where he served as the Department of Medicine's Quality and Patient Safety Officer and Founding Director of its Cardio-Oncology program, the only program in the state to be recognized by the International Cardio-Oncology Society's as a Gold Level Center of Excellence. Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Education record: ECFMG
Through 2011
Education Other ECFMG 2011 Medical Education Mahatma Gandhi Mission's Medical College, India (2007), MD Other University of Kentucky (2011), Master of Health Administration Health Administration Residency St. Elizabeth Youngstown Hospital (2015), Internal Medicine Fellowship MetroHealth Medical Center (2018) Fellowship Yale New Haven Medical Center (2019), Cardiac Imaging
Fellowship: MetroHealth Medical Center
Through 2018
Education Other ECFMG 2011 Medical Education Mahatma Gandhi Mission's Medical College, India (2007), MD Other University of Kentucky (2011), Master of Health Administration Health Administration Residency St. Elizabeth Youngstown Hospital (2015), Internal Medicine Fellowship MetroHealth Medical Center (2018) Fellowship Yale New Haven Medical Center (2019), Cardiac Imaging
Fellowship: Yale New Haven Medical Center (Cardiac Imaging)
Through 2019
Education Other ECFMG 2011 Medical Education Mahatma Gandhi Mission's Medical College, India (2007), MD Other University of Kentucky (2011), Master of Health Administration Health Administration Residency St. Elizabeth Youngstown Hospital (2015), Internal Medicine Fellowship MetroHealth Medical Center (2018) Fellowship Yale New Haven Medical Center (2019), Cardiac Imaging
Graduate education: University of Kentucky (Master of Health Administration Health Administration)
Through 2011
Education Other ECFMG 2011 Medical Education Mahatma Gandhi Mission's Medical College, India (2007), MD Other University of Kentucky (2011), Master of Health Administration Health Administration Residency St. Elizabeth Youngstown Hospital (2015), Internal Medicine Fellowship MetroHealth Medical Center (2018) Fellowship Yale New Haven Medical Center (2019), Cardiac Imaging
Official headshot: Portrait
<img src="https://profileplus.swmed.edu/facultydata/242240/images/arbune-amit-inset.jpg" class="card__image" itemprop="image" alt="Amit Arbune, M.D. " style="max-width:200px;" />
Medical school: Mahatma Gandhi Mission's Medical College, India (MD)
Through 2007
Education Other ECFMG 2011 Medical Education Mahatma Gandhi Mission's Medical College, India (2007), MD Other University of Kentucky (2011), Master of Health Administration Health Administration Residency St. Elizabeth Youngstown Hospital (2015), Internal Medicine Fellowship MetroHealth Medical Center (2018) Fellowship Yale New Haven Medical Center (2019), Cardiac Imaging
Official profile: Official profile
Biography Amit Arbune, M.D., M.H.A., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Cardiology. He serves as Medical Director for the Cardio-Oncology Clinic at Parkland Health. He also leads the cardio-oncology section for the Global Cancer Consortium and co-directs its certification training, which aims to train cardiologists, hematologists and oncologists, internists, advanced practice providers, and clinical pharmacists in the field of cardio-oncology. Dr. Arbune received his medical education at Mahatma Gandhi Mission's Medical College in India. He completed internal medicine residency training at North East Ohio Medical University in Youngstown, Ohio, followed by fellowship training in cardiovascular disease at Case Western Reserve University in Cleveland, Ohio, and in advanced cardiovascular imaging at Yale University in New Haven, Connecticut. He also holds a master's degree in healthcare administration from the University of Kentucky in Lexington. Prior to joining the UT Southwestern faculty in 2025, he was on the faculty at the University of Kentucky, where he served as the Department of Medicine's Quality and Patient Safety Officer and Founding Director of its Cardio-Oncology program, the only program in the state to be recognized by the International Cardio-Oncology Society's as a Gold Level Center of Excellence. Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Research interests: advanced cardiac imaging
Biography Amit Arbune, M.D., M.H.A., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Cardiology. He serves as Medical Director for the Cardio-Oncology Clinic at Parkland Health. He also leads the cardio-oncology section for the Global Cancer Consortium and co-directs its certification training, which aims to train cardiologists, hematologists and oncologists, internists, advanced practice providers, and clinical pharmacists in the field of cardio-oncology. Dr. Arbune received his medical education at Mahatma Gandhi Mission's Medical College in India. He completed internal medicine residency training at North East Ohio Medical University in Youngstown, Ohio, followed by fellowship training in cardiovascular disease at Case Western Reserve University in Cleveland, Ohio, and in advanced cardiovascular imaging at Yale University in New Haven, Connecticut. He also holds a master's degree in healthcare administration from the University of Kentucky in Lexington. Prior to joining the UT Southwestern faculty in 2025, he was on the faculty at the University of Kentucky, where he served as the Department of Medicine's Quality and Patient Safety Officer and Founding Director of its Cardio-Oncology program, the only program in the state to be recognized by the International Cardio-Oncology Society's as a Gold Level Center of Excellence. Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Research interests: cancer therapy-related cardiotoxicity
Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Research interests: cardiac CT
Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Research interests: cardiac MRI
Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Research interests: cardio-oncology
Amit Arbune, M.D., M.H.A., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Cardiology. He serves as Medical Director for the Cardio-Oncology Clinic at Parkland Health. He also leads the cardio-oncology section for the Global Cancer Consortium and co-directs its certification training, which aims to train cardiologists, hematologists and oncologists, internists, advanced practice providers, and clinical pharmacists in the field of cardio-oncology.
Research interests: immune checkpoint inhibitor myocarditis
Biography Amit Arbune, M.D., M.H.A., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Cardiology. He serves as Medical Director for the Cardio-Oncology Clinic at Parkland Health. He also leads the cardio-oncology section for the Global Cancer Consortium and co-directs its certification training, which aims to train cardiologists, hematologists and oncologists, internists, advanced practice providers, and clinical pharmacists in the field of cardio-oncology. Dr. Arbune received his medical education at Mahatma Gandhi Mission's Medical College in India. He completed internal medicine residency training at North East Ohio Medical University in Youngstown, Ohio, followed by fellowship training in cardiovascular disease at Case Western Reserve University in Cleveland, Ohio, and in advanced cardiovascular imaging at Yale University in New Haven, Connecticut. He also holds a master's degree in healthcare administration from the University of Kentucky in Lexington. Prior to joining the UT Southwestern faculty in 2025, he was on the faculty at the University of Kentucky, where he served as the Department of Medicine's Quality and Patient Safety Officer and Founding Director of its Cardio-Oncology program, the only program in the state to be recognized by the International Cardio-Oncology Society's as a Gold Level Center of Excellence. Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Research interests: implementation science
Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Research interests: PET imaging
Biography Amit Arbune, M.D., M.H.A., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Cardiology. He serves as Medical Director for the Cardio-Oncology Clinic at Parkland Health. He also leads the cardio-oncology section for the Global Cancer Consortium and co-directs its certification training, which aims to train cardiologists, hematologists and oncologists, internists, advanced practice providers, and clinical pharmacists in the field of cardio-oncology. Dr. Arbune received his medical education at Mahatma Gandhi Mission's Medical College in India. He completed internal medicine residency training at North East Ohio Medical University in Youngstown, Ohio, followed by fellowship training in cardiovascular disease at Case Western Reserve University in Cleveland, Ohio, and in advanced cardiovascular imaging at Yale University in New Haven, Connecticut. He also holds a master's degree in healthcare administration from the University of Kentucky in Lexington. Prior to joining the UT Southwestern faculty in 2025, he was on the faculty at the University of Kentucky, where he served as the Department of Medicine's Quality and Patient Safety Officer and Founding Director of its Cardio-Oncology program, the only program in the state to be recognized by the International Cardio-Oncology Society's as a Gold Level Center of Excellence. Dr. Arbune's research interests intersect cardio-oncology and advanced cardiology imaging, with an emphasis on detection, characterization, and management of cancer therapy-related cardiotoxicity. His work frequently explores immune checkpoint inhibitor-associated myocarditis, anthracycline and 5‑fluorouracil cardiotoxicity, and complex cardio‑oncologic cases involving arrhythmias, pericardial disease, and heart failure, using modalities such as cardiac MRI, cardiac CT, PET, multimodality imaging, and strain analysis. He also investigates imaging‑based predictors of outcomes in breast cancer patients, applies implementation science frameworks to develop cardio‑oncology services, and contributes to case‑based learning on rare or severe presentations of drug‑induced cardiac injury. Altogether, his research highlights a sustained commitment to improving diagnostic precision, risk stratification, and clinical pathways for patients experiencing or at risk for cardiotoxic effects of cancer therapies.
Residency: St. Elizabeth Youngstown Hospital (Internal Medicine)
Through 2015
Education Other ECFMG 2011 Medical Education Mahatma Gandhi Mission's Medical College, India (2007), MD Other University of Kentucky (2011), Master of Health Administration Health Administration Residency St. Elizabeth Youngstown Hospital (2015), Internal Medicine Fellowship MetroHealth Medical Center (2018) Fellowship Yale New Haven Medical Center (2019), Cardiac Imaging
1 source claim · Reviewed Sep 7, 2026
Professional role: Assistant Professor
Amit Arbune, M.D. Assistant Professor
